Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer by S. Siena et al.
ORIGINAL ARTICLE
Dynamic molecular analysis and clinical correlates
of tumor evolution within a phase II trial of
panitumumab-based therapy in metastatic
colorectal cancer
S. Siena1,2*, A. Sartore-Bianchi1,2, R. Garcia-Carbonero3, M. Karthaus4, D. Smith5, J. Tabernero6,
E. Van Cutsem7,8, X. Guan9, M. Boedigheimer9, A. Ang9, B. Twomey9, B. A. Bach9, A. S. Jung9,
& A. Bardelli10,11*
1Department of Hematology and Oncology, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy; 2Department of Oncology and
Hemato-Oncology, Universita` degli Studi di Milano, Milan, Italy; 3Department of Medical Oncology, Hospital Universitario 12 de Octubre, CNIO, CIBERONC,
Universidad Complutense, Madrid, Spain; 4Department for Hematology and Oncology, Staedt Klinikum Neuperlach and Harlaching, Munich, Germany;
5Department of Gastroenterology, University Hospital of Bordeaux, Hopital Haut Levaeque, Bordeaux, France; 6Department of Medical Oncology, Vall d’Hebron
University Hospital, Vall d’Hebron Institute of Oncology (VHIO), CIBERONC, Universitat Auto`noma de Barcelona, Barcelona, Spain; 7Department of Gastroenterology
and Digestive Oncology, University Hospitals Leuven, Leuven, Belgium; 8KU Leuven, Leuven, Belgium; 9Amgen Inc., Thousand Oaks, CA, USA; 10Candiolo Cancer
Institute-FPO, IRCCS, Candiolo, Italy; 11Department of Oncology, University of Torino, Candiolo, Italy
*Correspondence to: Prof. Salvatore Siena, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda and University of Milano, Piazza Ospedale Maggiore, 3, 20162
Milano, Italy. Tel: þ39-02-64442291; Fax: þ39-02-64442957; E-mail: salvatore.siena@unimi.it
Prof. Alberto Bardelli, Candiolo Cancer Institute-FPO and University of Torino, SP 142 km 3.95, Candiolo, 10060 Torino, Italy. Tel: þ39-011-9933235; Fax: þ39-011-9933225;
E-mail: alberto.bardelli@unito.it
Background: Mutations in rat sarcoma (RAS) genes may be a mechanism of secondary resistance in epidermal growth factor
receptor inhibitor-treated patients. Tumor-tissue biopsy testing has been the standard for evaluating mutational status;
however, plasma testing of cell-free DNA has been shown to be a more sensitive method for detecting clonal evolution.
Materials and methods: Archival pre- and post-treatment tumor biopsy samples from a phase II study of panitumumab in
combination with irinotecan in patients with metastatic colorectal cancer (mCRC) that also collected plasma samples before,
during, and after treatment were analyzed for emergence of mutations during/post-treatment by next-generation sequencing
and BEAMing.
Results: The rate of emergence of tumor tissue RAS mutations was 9.5% by next-generation sequencing (n¼ 21) and 6.3% by
BEAMing (n¼ 16). Plasma testing of cell-free DNA by BEAMing revealed a mutant RAS emergence rate of 36.7% (n¼ 39).
Exploratory outcomes analysis of plasma samples indicated that patients who had emergent RASmutations at progression had
similar median progression-free survival to those patients who remained wild-type at progression. Serial analysis of plasma
samples showed that the first detected emergence of RASmutations preceded progression by a median of 3.6months (range,
0.3 to 7.5months) and that there did not appear to be a mutant RAS allele frequency threshold that could predict near-term
outcomes.
Conclusions: This first prospective analysis in mCRC showed that serial plasma biopsies are more inclusive than tissue biopsies
for evaluating global tumor heterogeneity; however, the clinical utility of plasma testing in mCRC remains to be further
explored.
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Introduction
Activating mutations in the rat sarcoma (RAS) gene family (e.g.
KRAS and NRAS, exons 2, 3, and 4) are well-established bio-
markers for lack of response in patients with metastatic colorectal
cancer (mCRC) receiving anti-epidermal growth factor receptor
(EGFR) antibody therapy [1]. Although patients who have wild-
type RAS tumors before treatment initiation may derive benefit
from anti-EGFR therapy, most will ultimately progress [1]. This
progression may be attributed to continued clonal evolution and
diversification, including the possibility of secondary (acquired)
resistance to therapy resulting from selective pressure [2].
Mutations in RAS genes have been implicated as one mechanism
of secondary resistance in EGFR inhibitor-treated patients, and
mutation emergence has been detected in plasma samples during
anti-EGFR therapy [3–5]. Tumor driver alterations in genes other
than RAS have also been shown to be prognostically important
for tumor growth and may play a role in clonal diversification
and acquired resistance during therapy [6].
Tumor-tissue biopsy testing has been the standard for evaluat-
ing tumor mutational status. However, biopsies are invasive,
contain only a fraction of the total tumor heterogeneity, and may
not capture the full spectrum of potential additional genetic
changes that occur during treatment [7]. More recently, plasma
testing using next-generation sequencing (NGS) techniques or
BEAMing (beads, emulsion, amplification, magnetics) of cell-
free DNA (cfDNA) have been shown to be sensitive, reprodu-
cible methods of detecting clonal evolution of mutations [8].
Sequential plasma sample analysis may allow for the assessment
of cfDNA for global mutation status in real time [9] and may re-
flect a more global sample of total tumor heterogeneity.
Few studies have evaluated paired tumor biopsy and plasma
samples for mutation detection and prospective studies in this
setting are lacking. We present results from the prospective, phase
II, 20070820 study of patients with KRAS exon 2 wild-type
mCRC who received treatment with panitumumab plus irinote-
can (ClinicalTrials.gov, NCT00891930). Designed in 2007 and
completed in July 2013, the study was initially designed to test
whether KRAS mutation emergence was associated with the de-
velopment of secondary resistance to panitumumab therapy.
With additional findings reporting the impact of extended RAS
mutations [1], the exploratory hypothesis extended to include
other RAS family genes.
Materials and methods
Experimental design
Patients enrolled in part 1 received panitumumab 6mg/kg plus irinote-
can 180mg/m2 every 2weeks until progression. After progression, pa-
tients were eligible for part 2, which required a second biopsy from the
same tumor lesion (e.g. paired biopsy) for those with an objective re-
sponse or stable disease under treatment with panitumumab in part 1,
with the underlying rationale of studying mechanisms of acquired resist-
ance and excluding primary resistant tumors (Figure 1A). The primary
end point was objective response rate (supplementary Table S1, available
at Annals of Oncology online); secondary end points were progression-
free survival (PFS), overall survival (OS), and safety, which have been
previously reported [10]. The coprimary objective was to determine
whether acquired resistance to panitumumab in patients with wild-type
KRAS exon 2 mCRC correlated with the emergence of mutant KRAS
tumors.
Biomarker analysis
The objective of the biomarker analyses was to evaluate whether the DNA
mutation status of potential tumor-related biomarkers (including RAS)
changed in clonal populations of tumor cells during therapy or at pro-
gression. The mutation status of a panel of cancer driver gene mutations
was evaluated using pretreatment (archival primary or metastatic biopsy
tissue) and post-treatment samples from the same lesions where possible.
RAS mutation status was determined by examining KRAS exons 2
(codons 12 and 13), 3 (codons 59 and 61), and 4 (codons 117 and 146);
NRAS exons 2 (codons 12 and 13) and 3 (codons 59 and 61); and HRAS
exons 2 (codons 12 and 13), 3 (codons 59 and 61), and 4 (codon 117 but
not codon 146) from tumor tissue. Plasma biopsies collected at screening
and weeks 9, 17, 25, 33, and 37 and once every 4weeks thereafter until
progression or study drug intolerability were also analyzed.
Tissue and plasma biomarker testing was carried out according to the
analysis plan (Figure 1B); analysts were blinded to clinical data and pa-
tient outcomes (see supplementary materials, available at Annals of
Oncology online). Because progressive disease as best response suggests
primary resistance and the study was aimed at understanding molecular
mechanisms of secondary resistance, patients with a best response of pro-
gressive disease were not analyzed. For patients with wild-type RAS
tumor tissue at baseline with a best response of at least stable disease,
plasma samples were analyzed at baseline and time of progression. For
patients with wild-type RAS tumor tissue at baseline with mutant RAS
tumor results at time of progression, all available plasma sample time
points were analyzed to determine the timing and change in allele frac-
tion of mutation emergence.
The study protocol was approved by an independent ethics committee
at each study site; all patients provided written informed consent before
study entry.
Results
Patients
Overall, 76 patients with wild-type KRAS exon 2 mCRC were en-
rolled; 74 patients received1 dose of panitumumab and were
included in the tumor tissue analysis. Twenty-nine patients had
paired evaluable RAS status at baseline and progression and were
included in the NGS tissue analysis. Of the 39 patients with evalu-
able plasma samples at baseline, 30 had wild-type RAS at baseline
and paired post-treatment samples and were included in the
BEAMing plasma analysis. Overall, 15 patients had both evalu-
able paired tissue and plasma samples (Figure 1B). Baseline
demographics and disease characteristics were generally similar
between tumor tissue and plasma testing groups (supplementary
Table S2, available at Annals of Oncology online).
Paired tumor biopsies revealed limited emergent
mutations
Baseline mutations were determined using DNA extracted from
FFPE tumor tissue from 74 patients with wild-type KRAS exon 2
tumors.Mutation rates were determined byNGSof a 51-gene panel
(Table 1) with the subset of EGFR pathway-related genes prespeci-
fied in the study protocol. At baseline, themost commonlymutated
gene was TP53 (61%). Consistent with previous studies [11],
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Figure 1. (A) Study schema and (B) patient tumor RAS status results determined by tissue and plasma testing biomarker analyses. The RAS
status of pre-and post-treatment patient tumor samples were analyzed by each testing method. Total patient samples and the number of pa-
tients whose RAS status did (e.g. WT!MT, MT!WT) or did not (WT!WT, MT!MT) change pre- to post-treatment are indicated. The num-
bers in the central intersection of the Venn diagram represent those cases for whom comparisons of analyses by the three indicated
methods and source of samples were available. Samples were categorized as discordant if the results varied between testing methods.
BEAM, beads, emulsion, ampliﬁcation, magnetics; CT, computed tomography; IGF-1 R, insulin-like growth factor receptor 1; MRI, magnetic res-
onance imaging; MT, mutant; ND, no data; NGS, next-generation sequencing; Q2W, every 2weeks; Q4W, every 4weeks; WT, wild-type. aBlood
collection for plasma analysis at week 37 and every 4weeks thereafter until disease progression intolerability. bBased on ﬁrst restaging CT or
MRI. cNine patients were either not doing or unevaluable for tumor response assessment. dOnly patients who had an objective response or
stable disease after part 1 underwent a second biopsy. eA monoclonal antibody that inhibits the insulin-like growth factor 1 (IGF-1 R) path-
way. fPatients without both before-treatment and after-treatment samples for both tests were not characterized as discordant. gPatient was
characterized as RAS wild-type at baseline by NGS.
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extended RAS analysis revealed that 22% (n¼ 16/74) of
the screened wild-type KRAS exon 2 samples had other
activating RASmutations, and 7% had BRAFmutations at baseline
(supplementary Table S3, available atAnnals of Oncology online).
To study the emergence of drug resistance and tumor evolution
with anti-EGFR therapy, we analyzed 29 patients with available
tumor tissue samples at baseline and time of progression. Four pa-
tients with existing TP53 mutations gained additional coding-
region TP53 mutations and six patients had emergent mutations.
Of the six with emergent mutations, three gained TP53mutations
(one also had a baselineNRAS [Q61H] mutation that was not de-
tected at progression), one patient gained an SMAD4 mutation,
one patient gained both IDH1 and KRAS (G13D) mutations, and
one patient gained aKRAS (Q61H)mutation.
Of the 29 paired patient pre- and post-treatment tissue sam-
ples, 21 were wild-type RAS at baseline. The mutant RAS emer-
gence rate was 9.5% (n¼ 2/21; 95% CI, 1% to 30%). BEAMing
was used to further evaluate the mutant RAS emergence rate as it
is reported to have a sensitivity of 0.01% [12] versus 10% mu-
tant fraction sensitivity of NGS (see supplementary materials,
available at Annals of Oncology online). Of the 29 paired patient
tissue samples tested using NGS, 17 were evaluated by BEAMing.
Because of limited DNA availability and because few emergent
mutations were observed using NGS, only RAS status was tested
with BEAMing. Sixteen patients were wild-type RAS at baseline
and the mutant RAS emergence rate by BEAMing of tissue was
6.3% (n¼ 1/16; supplementary Table S4, available at Annals of
Oncology online).
Detection for RASmutations improved with plasma
cfDNA profiling
Of the 39 patients with plasma samples at baseline (supplemen
tary Table S4, available at Annals of Oncology online), 31 had
wild-type RAS cfDNA and 8 had mutant RAS cfDNA when ana-
lyzed by BEAMing (Figure 2). One patient who was evaluated as
wild-type RAS at baseline did not have evaluable samples at pro-
gression. Of the 30 patients with wild-type RAS cfDNA plasma
samples, 19 had wild-type RAS and 11 had mutant RAS at pro-
gression. The mutant RAS emergence rate in plasma samples by
BEAMing was 36.7% (n¼ 11/30). Of the 8 patients with mutant
RAS plasma samples at baseline, 5 retained RASmutations and 3
had wild-type RAS status at progression. The 3 patients identified
as mutant RAS at baseline and wild-type at progression all had
low frequencies of a single mutant RAS allele detected at baseline
(0.04% KRAS G12A, 0.05% KRAS Q61H, and 0.03% NRAS
Q61H, respectively).
In patients with paired tumor tissue biopsy and paired plasma
samples that were wild-type RAS at baseline (n¼ 14; supplemen
tary Table S4, available at Annals of Oncology online), the mutant
RAS emergence rate in tissue samples by BEAMing was 7.1%,
(n¼ 1/14), similar to the 9.5% obtained by NGS of tumor tissue.
In contrast, the mutant RAS emergence rate by BEAMing in
the cfDNA plasma samples was 57.1% (n¼ 8/14). The difference
in the emergence rates determined by BEAMing of tissue sam-
ples and cfDNA plasma samples was statistically significant
(P¼ 0.008, McNemar’s test).
Emergence of detectable RASmutations in plasma
was not associated with immediate resistance to
therapy
To further evaluate the potential impact of RAS mutation emer-
gence in plasma, an exploratory analysis of the 30 patients with
paired plasma samples who were wild-type RAS at baseline (19
wild-type at progression, 11 with emergent RAS mutations at
progression) were evaluated for clinical outcomes. The emer-
gence of RAS mutations at progression was not predictive of the
degree of radiologically observed cytoreduction measured as the
maximum percentage change of the SLD of target lesions (Figure
3A). In addition, for those who retained wild-type status at
progression (n¼ 19), median PFS (95% CI) was 5.0 (3.7–
9.2)months versus 7.4 (6.8–9.1)months for those with RAS
mutations at progression [hazard ratio (HR)¼1.08; 95%
CI, 0.492.38; P¼ 0.84 for mutation effect].
Given the lack of a correlation between the presence of emer-
gent RAS mutations and both depth of response and the lack of
changes in the HR for progression and PFS, analyses to evaluate
whether the timing of mutant RAS emergence impacted treat-
ment outcomes were carried out.
Plasma samples collected during treatment were tested by
BEAMing in seriatim to conduct a temporal RAS analysis. Time-
to-progression analysis revealed that detection of mutant clones
during treatment did not correlate with an immediate transition
of clinical disease state; however, RAS mutation emergence pre-
ceded radiologic relapse for all patients (Figure 3B). Median
(range) lead time from the first detection of a RAS mutation to
radiologic progression was 3.6 (0.3 to 7.5)months. To better
understand the impact of the emergence of RASmutations on re-
sponse and relapse to EGFR blockade, we carried out longitudinal
assessment of plasma samples in multiple patients (Figure 3C
and supplementary Figure S1, available at Annals of Oncology
online).
Table 1. Cancer genes sequenced in tumor samples using the SuraSeq 51-
gene panel
Cancer genes sequenced
ABL1 FES JAK2 PIK3R1
AKT1 FGFR1 KIT PTCH1
AKT2 FGFR3 KRAS PTEN
BRAF FLT3 MEN1 PTPN11
CDH1 FOXL2 MET RB1
CDK4 GATA1 MPL RET
CDKN2A GNA11 NF2 SMAD4
CEBPA GNAQ NOTCH1 SMARCB1
CREBBP HIF1A NPM1 SMO
CTNNB1 HRAS NRASa SRC
ERBB2 IDH1 PAX5 STK11
EGFR IDH2 PDGFRA TP53
IKBKB PIK3CA VHL
Genes in bold represent whole exon sequencing; non-bolded genes rep-
resent hotspot sequencing. Genes marked with a gray box were wild-
type across all sample types.
aNRAS exon 4 was not included.
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Individual patient analysis illustrated initial detection of RAS
mutations was variable, ranging from 2 to 8months after ther-
apy initiation (Figure 3B and C; supplementary Figure S1, avail-
able at Annals of Oncology online). The time of initial detection of
RAS mutations did not necessarily correlate with outcomes
(Figure 3B and C; supplementary Figure S1, available at Annals of
Oncology online). Once detected, the frequency of individual RAS
mutant allele levels fluctuated during treatment but the total RAS
mutation levels in a sample increased in most patients. A trend
was observed indicating that the highest frequency of total RAS
mutations detected were associated with the highest reported
SLD of a patient’s tumor (supplementary Figure S1, available at
Annals of Oncology online; patients 4 through 11); however, a
threshold to predict disease progression could not be established.
Discussion
Results from this study indicate that RASmutations emerge dur-
ing panitumumab treatment, that the detected emergence rates
are dependent on the DNA source (plasma versus tumor tissue)
and analytic technique (NGS versus BEAMing), and that the
evaluation of plasma samples can provide a sensitive dynamic
picture of global clonal heterogeneity.
Exploratory outcomes analysis of plasma samples from pa-
tients with wild-type RAS at baseline revealed that patients with
emergent RAS mutations at progression had no significant
changes in immediate direction of tumor burden and had similar
median PFS to those whose RAS status remained wild-type at
progression. Given that all patients eventually relapsed, this
indicates that a threshold might be reached for RAS clones to im-
pact clinical outcome and that other potential (non-RAS) mech-
anisms of resistance may have contributed to progression.
These results analyzing plasma samples at baseline and pro-
gression are consistent with the initial analysis of 164 patients
from ASPECCT, a phase III panitumumab monotherapy study,
which showed that patients with emergent RASmutations at pro-
gression (detected by plasma NGS; 0.1% detection limit) had
similar PFS and OS versus patients whose RAS status remained
wild-type at progression [13].
Analysis of serial plasma samples revealed that after initial de-
tection of the mutant RAS allele during treatment, many patients
continued to derive clinical benefit from panitumumab plus iri-
notecan, as determined by radiographic monitoring. The median
lead time from initial RAS mutant detection to progression was
3.6months (range, 0.3 to 7.5months). Together, this indicates
that patient RAS status may be the result of a complex dynamic of
heterogeneous clones and that emergent RASmutations detected
in plasma using sensitive assays may not necessarily be associated
with worse outcomes in panitumumab-treated patients.
However, when clonal dynamics of individual patients were ana-
lyzed, the highest levels of total RAS mutations appeared to be
associated with the highest SLD of a patient’s tumor.
In a previous study of mCRC treated with anti-EGFR inhibi-
tors in the first-line setting, the emergence of mutant alleles also
preceded progression (limit of detection, at least 15% across
methods) [5]. Another study also found that emergence of RAS
or EGFR extracellular domain mutations correlated with clinical
response after treatment with panitumumab or cetuximab in the
first-, second-, or third-line settings.
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Figure 2. Plasma testing schema and results. PD, progressive disease; RAS, rat sarcoma; t, time. aAll patents included were supposed to have
a best response of at least stable disease; however, two patients who were mutant to mutant (progressive disease, n¼ 1; unevaluable, n¼ 1)
and one patient who was wild-type to wild-type (progressive disease) were analyzed.
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This study also provides prospective data on the emergence rates
of mutations by NGS with a subset of 51 genes during anti-EGFR
therapy. When tissue samples were evaluated, remarkably limited
changes were found. No new BRAFmutations were found, in con-
trast with a previous study [14]. Previous studies also reported
emergence of MEK as well as amplification of MET and HER2 in
patients treated with anti-EGFR antibodies [5, 15]; however, these
genes were not evaluated here. The present study reported emer-
gence of an IDH1mutation in a post-treatment biopsy, suggesting
a possible association between its emergence and development of
secondary resistance to anti-EGFR therapy [16]. However, it is also
possible that the detection of this mutation was caused by clonal
hematopoiesis or contaminating white blood cells, as has been pre-
viously reported for an IDH2mutation [17].
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This study had several limitations. First, it was not intended to
determine a RAS mutation threshold that was predictive of a
change in clinical course. Furthermore, although this is one of the
largest datasets of plasma testing of mutant RAS emergence in
mCRC, the study included small patient numbers. Nonetheless,
results from this study track consistently with results from previ-
ous work [3–5, 18]. Additionally, the combination with irinote-
can may have impacted patient sensitivity and/or selection
pressure of emerging clones to panitumumab. However, to our
knowledge, emergent RAS mutations have not been described in
response to irinotecan, and clinical correlation results from our
paired analysis of plasma samples were consistent with a panitu-
mumab monotherapy study [13]. The prospectively defined ap-
proach to testing RAS status at progression may also have limited
analyses; only baseline and progression samples were analyzed for
patients identified as having no emergent RAS mutations,
whereas all samples from all available time points were analyzed
for patients identified as having mutant RAS at progression. Of
note, there were tumors classified as mutant RAS at baseline and
wild-type RAS at progression. It is unknown whether this was
due to reversion to wild-type, the sensitivity threshold of the ana-
lysis method, or the occurrence of false positives.
In summary, RASmutations emerged in 36.7% of patients who
developed acquired resistance to panitumumab plus irinotecan,
consistent with previous studies [3, 4, 13, 18]. The first detected
emergence of RAS mutations in plasma preceded progression by
a median of 3.6months (range, 0.3 to 7.5months) and did not
correlate with outcomes nor was it associated with immediate re-
sistance to therapy. This study is one of the first prospective ana-
lyses to show that liquid biopsies are more comprehensive than
tissue-based studies for understanding the potential mechanisms
of resistance to targeted agents. Additional prospective studies
with other technologies, including the analysis of truncal muta-
tions (e.g. APC variants), are needed to establish threshold values
of mutant allele frequency from plasma to accurately characterize
clinical progression. The planned CHRONOS trial of rechallenge
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with panitumumab in the third-line setting for mCRC is expected
to help determine this threshold.
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